Ramiro Guerrero Acquires 78,239 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 78,239 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average cost of $1.39 per share, with a total value of $108,752.21. Following the completion of the purchase, the director directly owned 689,081 shares in the company, valued at $957,822.59. The trade was a 12.81% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero acquired 46,620 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.35 per share, for a total transaction of $62,937.00.
• On Wednesday, August 26th, Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Up 5.4%

Shares of MAIA opened at $1.37 on Thursday. The firm has a market capitalization of $83.34 million, a P/E ratio of -2.21 and a beta of 0.25. MAIA Biotechnology, Inc. has a 12-month low of $0.87 and a 12-month high of $3.19. The firm has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.43.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Institutional Trading of MAIA Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the stock. Solas Capital Management LLC bought a new position in MAIA Biotechnology in the second quarter worth approximately $4,364,000. Centric Wealth Management bought a new stake in MAIA Biotechnology during the 2nd quarter valued at $1,107,000. Cable Car Capital LP bought a new stake in MAIA Biotechnology during the 2nd quarter valued at $741,000. BlackRock Inc. purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter worth $580,000. Finally, Geode Capital Management LLC lifted its holdings in shares of MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after buying an additional 25,684 shares during the period. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.